{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:03:51Z","timestamp":1790190231795,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.nucmedbio.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T05:49:11Z","timestamp":1491371351000},"page":"47-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clinical results and economic considerations of 68 Ga-PSMA and radiolabeled choline in prostate cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Laura","family":"Evangelista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Bonavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40336-013-0016-0","article-title":"Comparative studies among radiolabeled choline positron emission tomography, histology of primary tumour and other imaging modalities in prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Evangelista","year":"2013","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MNM.0000000000000040","article-title":"Meta-analysis of (11)C-choline and (18)F-choline PET\/CT for management of patients with prostate cancer","volume":"35","author":"von Eyben","year":"2014","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1515\/cclm-2013-0675","article-title":"Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET\/CT in restaging prostate cancer patients: a meta-analysis","volume":"52","author":"Treglia","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","author":"von Eyben","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0040","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","article-title":"Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging","volume":"36","author":"Kabasakal","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","article-title":"Early dynamic imaging in 68Ga- PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2967\/jnumed.114.141887","article-title":"Gleason score at diagnosis predicts the rate of detection of 18F-choline PET\/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients","volume":"56","author":"Cimitan","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0055","first-page":"359","article-title":"Early detection of prostate cancer relapse by biochemistry and diagnostic imaging","volume":"59","author":"Evangelista","year":"2015","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-015-0548-8","article-title":"Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists","volume":"10","author":"Shakespeare","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.nucmedbio.2017.04.001_bb0065","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pros.22956","article-title":"Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process","volume":"75","author":"Demirkol","year":"2015","journal-title":"Prostate"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117301014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117301014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T23:51:24Z","timestamp":1535932284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117301014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":13,"alternative-id":["S0969805117301014"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}